# Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

> **NCT02962401** · PHASE2 · COMPLETED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 50 (actual)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT02962401
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-07
- **Primary completion:** 2020-08-31
- **Final completion:** 2023-04-13
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962401, "Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02962401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*